StreetInsider.com News Articles

Form 424B5 Nexentis Technologies

Tue, 23 Jun 2026 10:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26677462.html

Form 424B5 Nexentis Technologies

Tue, 23 Jun 2026 10:03:00 -0400

si-local-file:///var/storage/secattach/20260623/26677462.html

Form 8-K Nexentis Technologies For: Jun 22

Mon, 22 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260622/26673840.html

Form 8-K Nexentis Technologies For: Jun 22

Mon, 22 Jun 2026 16:49:00 -0400

si-local-file:///var/storage/secattach/20260622/26673840.html

MitoCareX Bio partners with Boltz on AI-driven SLC drug discovery

Mon, 22 Jun 2026 08:23:38 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its wholly owned subsidiary, MitoCareX Bio Ltd., has entered into an engagement with Boltz, PBC, an AI research lab focused on biomolecular foundation models, to identify novel small-molecule scaffolds targeting selected solute carrier (SLC) proteins.

Under the initiative, MitoCareX plans to combine its proprietary MITOLINE® algorithm platform with Boltz's foundation models for predicting biomolecular structure, binding affinity, and molecule design. The initial phase will focus on virtual screening campaigns for a selected set of SLC protein targets. The companies may expand the scope to additional targets depending on results from the initial phase.

MitoCareX will

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Mon, 22 Jun 2026 08:22:00 -0400

MITOLINE^®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

Neve Yarak, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has entered into an engagement with Boltz, PBC (“Boltz”), an AI research lab that

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Mon, 22 Jun 2026 08:22:00 -0400

MITOLINE^®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Mon, 22 Jun 2026 08:22:00 -0400

MITOLINE^®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

Mon, 22 Jun 2026 08:22:00 -0400

MITOLINE^®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets

MitoCareX Bio completes SLC transport protein structural analysis

Wed, 17 Jun 2026 07:33:13 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its wholly owned subsidiary, MitoCareX Bio Ltd., has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins, according to a press release issued June 17, 2026.

The analysis builds on MITOLINE, MitoCareX's proprietary sequence analysis and alignment algorithm, which has been used to prepare mitochondrial SLC25 carrier proteins for 3D modeling in support of structure-based drug discovery targeting cancers and inflammatory metabolic diseases.

MitoCareX said it identified additional SLC proteins outside the SLC25 family whose amino acid sequences appear compatible with the MITOLINE ruleset, suggesting these transporters may be amenable to MITOLINE-enabled

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Wed, 17 Jun 2026 07:32:00 -0400

Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand and refine its small-molecule discovery capabilities.

This work builds on MITOLINE^®, MitoCareX’s proprietary sequence analysis and alignment algorithm, which to date

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Wed, 17 Jun 2026 07:32:00 -0400

This work builds on MITOLINE^®, MitoCareX’s proprietary sequence analysis and alignment algorithm, which to date

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Wed, 17 Jun 2026 07:32:00 -0400

This work builds on MITOLINE^®, MitoCareX’s proprietary sequence analysis and alignment algorithm, which to date

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Wed, 17 Jun 2026 07:32:00 -0400

This work builds on MITOLINE^®, MitoCareX’s proprietary sequence analysis and alignment algorithm, which to date

Form 424B5 Nexentis Technologies

Mon, 15 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260615/26643708.html

Form 424B5 Nexentis Technologies

Mon, 15 Jun 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260615/26643708.html

Form 8-K Nexentis Technologies For: Jun 12

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26641005.html

Form 8-K Nexentis Technologies For: Jun 12

Fri, 12 Jun 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260612/26641005.html

Form 8-K Nexentis Technologies For: May 27

Wed, 27 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260527/26557815.html

Form 8-K Nexentis Technologies For: May 27

Wed, 27 May 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260527/26557815.html

Nexentis unit achieves drug discovery milestone with improved molecule

Mon, 18 May 2026 09:34:58 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary MitoCareX Bio Ltd. has generated an optimized hit molecule with improved pharmaceutical properties compared to the program's initial hit compound. The company described this as the first drug discovery milestone since Nexentis acquired MitoCareX.

The optimized molecule was developed using MitoCareX's MITOLINE algorithm platform, which creates 3D structural models of mitochondrial carrier proteins in the SLC25 family. The initial hit molecule underwent systematic medicinal chemistry optimization, resulting in improvements across key pharmaceutical parameters as of March 31, 2026.

MitoCareX is developing a small molecule drug candidate targeting a mitochondrial SLC25 carrier protein for

Nexentis subsidiary hits drug discovery milestone for cancer treatment

Mon, 18 May 2026 09:31:04 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its subsidiary MitoCareX Bio Ltd. achieved a drug discovery milestone by generating an optimized hit molecule with improved pharmaceutical properties compared to the program's initial compound.

The milestone represents progress in MitoCareX's drug discovery program targeting mitochondrial carrier proteins in the SLC25 family for potential cancer and inflammatory metabolic disease treatments. The company used its MITOLINE algorithm platform to identify the initial hit molecule and subsequently optimized it through medicinal chemistry work completed by March 31, 2026.

MitoCareX's program focuses on developing small molecule drug candidates targeting a mitochondrial SLC25 carrier protein. The MITOLINE algorithm,

Nexentis subsidiary hits drug discovery milestone for cancer treatment

Mon, 18 May 2026 09:31:04 -0400

MitoCareX's program focuses on developing small molecule drug candidates targeting a mitochondrial SLC25 carrier protein. The MITOLINE algorithm,

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Mon, 18 May 2026 09:30:00 -0400

Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.

This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Mon, 18 May 2026 09:30:00 -0400

This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that